Evidence map›Paper›PMID 40700131›Full record

ArticleNeuroSci2025

Cognitive Performance and Quality of Life in Relapsing-Remitting Multiple Sclerosis: A BICAMS- and PROs-Based Study in a Mexican Public Hospital.

María Fernanda Castillo-Zuñiga, Rodolfo Manuel Roman-Guzman, Idefonso Rodríguez-Leyva

Abstract read
In one paragraph

Article in NeuroSci, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

María Fernanda Castillo-ZuñigaHospital Regional de Alta Especialidad Dr. Ignacio Morones Prieto, San Luis Potosí 78210, Mexico.ORCID 0009-0005-3171-6188
Rodolfo Manuel Roman-GuzmanHospital Regional de Alta Especialidad Dr. Ignacio Morones Prieto, San Luis Potosí 78210, Mexico.ORCID 0009-0006-7797-8973
Idefonso Rodríguez-LeyvaHospital Regional de Alta Especialidad Dr. Ignacio Morones Prieto, San Luis Potosí 78210, Mexico.ORCID 0000-0002-3316-1471

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCognitive impairment (CI) is a common and disabling symptom in patients with relapsing-remitting multiple sclerosis (RRMS), potentially emerging at any stage, including preclinical phases. Despite its impact on quality of life, CI often goes unrecognized, as clinical follow-up typically focuses on motor and sensory symptoms. Validated tools, such as the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and patient-reported outcomes (PROs), should be integrated into routine evaluations beyond the Expanded Disability Status Scale (EDSS).

objectiveThe objective of this study was to evaluate cognitive impairment and quality of life in patients with RRMS using the BICAMS and PROs.

methodsThis cross-sectional, descriptive study included patients with RRMS under follow-up at a tertiary hospital in San Luis Potosí, Mexico. Participants underwent cognitive screening with the BICAMS battery and completed the MSQoL-54 (quality of life), FSMC (fatigue), and MSIS-29 (functional impact) scales. Statistical analyses included ANOVA, the Kruskal-Wallis test, and Pearson correlations.

resultsNineteen patients were evaluated (73.7% female, mean age 36.5 ± 8.9 years). BICAMS results showed variable cognitive performance, with no significant differences across treatment groups for processing speed (

conclusionsCognitive impairment is common in RRMS and can be detected using brief assessment tools, such as the BICAMS. Incorporating cognitive screening and PROs into clinical practice is essential to guide comprehensive management.

Indexed as

brief international cognitive assessment for multiple sclerosis (BICAMS)cognitive impairment (CI)patient-reported outcomes (PROs)quality of life (QoL)relapsing–remitting multiple sclerosis (RRMS)

Identifiers

PMID40700131
PMCPMC12286033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.